Express Pharma

Sami/Sabinsa Group victorious in litigation against nutribiolink

2

NutriBioLink has agreed to discontinue any and all future sales of Curcumin to outside distribution

Sami/Sabinsa Group, the world leader in Curcumin for the dietary supplements industry, has successfully concluded a lawsuit against NutriBioLink, filed in the US District Court, New Jersey on July 30, 2014.

The lawsuit alleged that NutriBioLink and Olive Lifesciences were selling and distributing products that infringed upon Sami/Sabinsa Curcumin C3 Complex US Patent 5,861,415 (the ‘415 Patent), which protects compositions, methods of use, and methods of extraction of a nutritional supplement in the US. Specifically, other companies may not sell imitations of Sami/Sabinsa’s unique compositions, nor market it for its antioxidant use, nor use the extraction method developed by Sami/Sabinsa and outlined in Sami/Sabinsa’s patent.

NutriBioLink has agreed to discontinue any and all future sales of Curcumin to outside distribution. The proposed Final Consent Judgment stipulates that the ’415 Patent is valid, enforceable, and properly issued by the US Patent and Trademark Office.

“We are pleased that once again the courts have reaffirmed that our ‘415 Patent is valid and enforceable,” said Dr Muhammed Majeed, Founder, Sami/Sabinsa group of companies. “Given how many times we have challenged IP infringing companies and how many times we have prevailed, one would hope companies considering theft of Sami/Sabinsa’s Intellectual Property would ultimately decide to develop their own instead.”

Previously, lawsuits filed against Prakruthi Products and HerbaKraft, for Sabinsa’s ‘415 patent, were successfully resolved in Sami/Sabinsa’s favour.

Comments are closed.